CDC strongly recommends twice-yearly lenacapavir as an HIV prevention option
The recommendation covers people weighing at least 35 kg and rests on two trials in which lenacapavir cut HIV infections by 100% and 96% against background incidence.
Emtricitabine Tenofovir Disoproxil Fumarate
3 articles published between June 20, 2025 and September 19, 2025.
WHO issues guidance on twice-yearly lenacapavir for HIV prevention
The guidelines pair the new injectable with a second, quieter recommendation: use simplified rapid diagnostic testing to start and continue long-acting PrEP, rather than more complex assays.
FDA approves a twice-yearly injection for HIV prevention
Lenacapavir is the first HIV pre-exposure prophylaxis given every six months. Two phase 3 trials found zero and two infections in the lenacapavir groups against background rates above 2 per 100 person-years.